Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
| Market Cap | $46.25M-85.2% |
| Revenue (ttm) | n/a+318.0% |
| Net Income | n/a-82.4% |
| EPS | n/a+37.5% |
| Shares Out | 19.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,258,986 |
| Open | $2.58 |
| Previous Close | $2.55 |
| Day's Range | $2.31 - $2.60 |
| 52-Week Range | $2.30 - $20.56 |
| Beta | 1.90 |
| Analysts | Buy |
| Price Target | $22.50(+845.38%) |
| Earnings Date | n/a |
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Tonix Pharmaceuticals Holding Corp. Stock Analysis — InsiderScore
Tonix Pharmaceuticals Holding Corp. scored higher than 9% of companies evaluated by InsiderBuying, and ranked 80th out of 107 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Tonix Pharmaceuticals Holding Corp. bought $47.9K of stock across 2 purchases in the last 90 days, the largest of them $27.6K.
The average purchase added about 42% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TNXP stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TNXP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TNXP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TNXP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TNXP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TNXP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TNXP
| VTIVanguard Morningstar Total Stock Market ETF | $1.96M |
| IWMiShares Russell 2000 ETF | $1.08M |
| VXFVanguard Extended Market ETF | $955.81K |
| FESMFidelity Enhanced Small Cap ETF | $541.63K |
| VTWOVanguard Russell 2000 ETF | $490.31K |
| IWNiShares Russell 2000 Value ETF | $402.25K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TNXP’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong Tonmya revenue growth (37% QoQ) and expanding insurance coverage offset analyst concerns about valuation and funding risks.
Recent Insider Activity
Insider Score Trend Over Time
+11.5 since Sep 23Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
